Approval · Notice of Compliance 25472 · 2021
INVANZ: Notice of Compliance 25472
Issued March 17, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25472
- Date
- March 17, 2021
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the product monograph with the risk of hypersinsitivity vasculitis and to migrate to the 2016 format
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| INVANZ | Not yet assigned | — |
Medicinal ingredients
- ERTAPENEM SODIUM 1 G per VIAL